Phosphaplatins and their use in the treatment of cancers resistant to cisplatin and carboplatin

摘要: The present invention provides phosphaplatins, stable isolated monomeric phosphato complexes of platinum (II) and (IV), methods use thereof for treating cancers, including cisplatin- carboplatin-resistant cancers. Unlike cisplatin, these do not readily undergo hydrolysis are quite soluble in aqueous solutions. Moreover, complexes—unlike carboplatin, related platinum-based anti-cancer agents—do bind DNA. Rather, data suggests that phosphaplatins trigger overexpression fas fas-related transcription factors some proapoptotic genes such as Bak Bax. Nevertheless, the exhibit tremendous cytotoxicity towards cancer cells. Thus, novel anticancer agents have a different molecular target than those art.